These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15939261)

  • 21. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH; Plummer R
    Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A global ranking approach to end points in trials of mechanical circulatory support devices.
    Felker GM; Anstrom KJ; Rogers JG
    J Card Fail; 2008 Jun; 14(5):368-72. PubMed ID: 18514927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
    Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
    J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
    D'Haens G; Sandborn WJ; Feagan BG; Geboes K; Hanauer SB; Irvine EJ; Lémann M; Marteau P; Rutgeerts P; Schölmerich J; Sutherland LR
    Gastroenterology; 2007 Feb; 132(2):763-86. PubMed ID: 17258735
    [No Abstract]   [Full Text] [Related]  

  • 28. Combining radiotherapy and angiogenesis inhibitors: clinical trial design.
    Citrin D; Ménard C; Camphausen K
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):15-25. PubMed ID: 16377411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trials design and treatment tailoring: general principles applied to breast cancer research.
    Therasse P; Carbonnelle S; Bogaerts J
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):98-105. PubMed ID: 16431124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are we ready to use surrogate end points and surrogate tissues to evaluate response to chemopreventive and therapeutic intervention?
    Lotan R
    Clin Cancer Res; 2000 Jun; 6(6):2126-8. PubMed ID: 10873060
    [No Abstract]   [Full Text] [Related]  

  • 31. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
    Lippman SM; Heymach JV
    Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Missing data methods for the assessment of surrogate outcomes and treatment mechanisms in clinical trial substudies.
    Galbraith S; Marschner IC; Simes J
    Stat Med; 2006 Feb; 25(3):415-31. PubMed ID: 16217855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surrogate end points cloud DES trials.
    Kahn J
    J Interv Cardiol; 2006 Feb; 19(1):117-9. PubMed ID: 16483352
    [No Abstract]   [Full Text] [Related]  

  • 34. Imaging surrogate end points in heart failure trials.
    Bettari L; Borges-Neto S
    Heart Fail Clin; 2011 Oct; 7(4):509-18. PubMed ID: 21925434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer.
    Hughes MD
    Stat Methods Med Res; 2008 Oct; 17(5):487-95. PubMed ID: 18285440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review.
    Amby LK; Seremetis S; Obergfell A; Bjerre J
    Blood Coagul Fibrinolysis; 2009 Oct; 20(7):488-93. PubMed ID: 19543078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Surrogate end points].
    Bobbio M
    Ital Heart J Suppl; 2000 Jul; 1(7):877-9. PubMed ID: 10935731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers and surrogate end points in clinical trials of tuberculosis treatment.
    Davies GR; Phillips PP; Nunn AJ
    J Infect Dis; 2007 Aug; 196(4):648-9; author reply 649-50. PubMed ID: 17624855
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.